Protocol Ledger

NCT04603807 · Phase III · ACTIVE NOT RECRUITING

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

Interventional Phase III clinical trial protocol NCT04603807 sponsored by Roche / Genentech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-09-30 Enrollment: 217 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04603807
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)217 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04603807
Protocol FieldVerified Registry Value
NCT IdentifierNCT04603807
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment217 participants (ACTUAL)
Registered Start Date2021-09-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04603807
Hospital Research SiteLocationSite Profile
Jilin Cancer HospitalChangchun, ChinaOpen Hospital Dossier ->
The Second Xiangya Hospital of Central South UniversityChangsha, ChinaOpen Hospital Dossier ->
Hunan Cancer HospitalChangsha, ChinaOpen Hospital Dossier ->
West China Hospital,Sichuan UniversityChengdu, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI